Inventiva (NASDAQ:IVA) Given “Buy” Rating at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Inventiva (NASDAQ:IVA) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $20.00 price objective on the stock.

Several other analysts also recently weighed in on the company. Guggenheim boosted their target price on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. HC Wainwright started coverage on Inventiva in a report on Wednesday, September 3rd. They issued a “buy” rating and a $20.00 target price for the company. Finally, Piper Sandler started coverage on Inventiva in a research report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

Inventiva Price Performance

Inventiva stock opened at $6.30 on Tuesday. Inventiva has a fifty-two week low of $1.60 and a fifty-two week high of $6.50. The stock has a 50-day simple moving average of $4.83 and a 200-day simple moving average of $3.82.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,715 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.